Sheppard plans to contribute further to publications and patent introductions. He is excited to witness his first wave of student mentees graduate with their doctorates, and Dr. Those interests developed into an intense curiosity for microbiology as well, and over time he became interested in the interface between the immune system and cancer, which led him to immunotherapy. Taking trips with his parents to the Caribbean and Sri Lanka from the young age of 6 inspired him to think about immunizations needed for travel and how they worked. Sheppard's mind to the fascinating subject of vaccines. Sheppard is proud of having been a founding member of the GSK Oncology Cell Therapy unit where he was instrumental in exercising GSK's option to acquire a new cell therapy, as well as having won the Team Science Recognition Award 'Advanced T cell Engineering Against Malignancies (A-TEAM)', which he earned from the Society for Immunotherapy of Cancer (SITC) in 2020. He counts as a career highlight an ongoing clinical trial that was shaped by his collaborative efforts through negotiation, trial design and regulatory approvals. Sheppard has been the inventor of patents, contributor to numerous peer-reviewed publications as either first or senior author and held an appointment as a lecturer in molecular medicine at Magdalen College Oxford between 20. Sheppard was recruited to University of Pennsylvania Center for Cellular Immunotherapies.ĭr. in Philadelphia, PA from 2018 to 2019 where he opened an Investigational New Drug (IND) application for a novel CAR-T therapy. Sheppard became an executive director program leader for Tmunity Therapeutics Inc. He graduated from the Esprit program as the Head of External Cooperations for the Oncology Cell Therapy unit, and Early Development Leader for TCR-T programs from 2016 to 2018. Subsequently, Neil was selected for the prestigious 'Esprit R&D' rotational leadership development program at GSK, where he completed three rotations of one year each between 20 in the Regenerative Medicine unit in Collegeville, PA, the Ethnopharmacology unit in Sydney, Australia, and finally in the Immuno-Oncology in the Combinations Discovery Performance Unit in Collegeville, PA. Sheppard's career include being a senior scientist and principal scientist in vaccine research for Pfizer from 2007 until 2013 in the UK and San Diego, CA. Sheppard embarked on a career in the pharmaceutical and biotech industry. Sheppard received a Bachelor of Science in immunology from the University of Bristol in 2002 and a Doctor of Philosophy in molecular retrovirology and vaccines research at the University of Oxford in 2007, after which Dr. Prior to embarking upon his professional journey, Dr. Sheppard is also an adjunct associate professor of pathology and laboratory medicine. He leads a team of scientists that includes graduate students and postdoctoral researchers, as well as university research staff as they work on innovative cell therapies. Sheppard is currently on staff at the University of Pennsylvania Center for Cellular Immunotherapies, where he is head of the T Cell Engineering Laboratory (TCEL) and director of Research Technologies and Innovation. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Īcting on a lifelong fascination with immunology, Dr. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Sheppard, DPhil, has been included in Marquis Who's Who. PHILADELPHIA, PA, J/24-7PressRelease/ - Neil C.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |